Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of DirectorsGlobeNewsWire • 06/13/22
Verve Therapeutics to Participate in the 2022 Jefferies Healthcare ConferenceGlobeNewsWire • 06/01/22
Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/10/22
Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022GlobeNewsWire • 05/09/22
Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone SymposiaGlobeNewsWire • 04/26/22
Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular DiseaseGlobeNewsWire • 04/04/22
Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease ConferenceGlobeNewsWire • 03/24/22
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/14/22
Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing ProgramsGlobeNewsWire • 01/10/22
Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/22
These were the 10 best performing IPOs of 2021 amid a record year for stock market debutsBusiness Insider • 12/15/21
Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial OfficerGlobeNewsWire • 11/29/21
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial ResultsGlobeNewsWire • 11/10/21
Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human PrimatesGlobeNewsWire • 11/09/21
Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing SummitGlobeNewsWire • 10/21/21
Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/27/21
Verve Therapeutics' Gene-Editing Therapy Shows Encouraging Preclinical Action In Cardiovascular DiseaseBenzinga • 09/23/21
Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene EditingSeeking Alpha • 08/24/21